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The monoclonal antibody Ki-67 recognizes a nuclear antigen expressed in the Gp S, G„ and M phase of the cell 
cycle and has been used extensively as an indicator of cellular proliferation in malignant gliomas, both in the labora­
tory and clinically. Recently, protein kinase C (PKC) inhibitors have been demonstrated to inhibit malignant glioma 
growth both in in vitro and in vivo. This study was undertaken to determine whether Ki-67 could function as an indi­
cator of cellular proliferation rate after PKC inhibition in gliomas and to explore cell cycle specificity of such inhibi­
tion. Both established and low-passage malignant glioma cell lines have previously been shown to be sensitive to 
growth inhibition by the PKC inhibitors staurosporine and tamoxifen in vitro (IC50 in the nanomolar and micromo­
lar ranges, respectively), as measured by cell numbers, pH] thymidine uptake, and flow-cytometric DNA analysis. 
However, in the same cells that are inhibited by staurosporine and tamoxifen on these assays, and on the 3-(4,5- 
dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium bromide (MTT) assay in the present study, the Ki-67 labeling index 
paradoxically increased in a dose-related manner with the same treatments, as measured by immunohistochemistry and 
confirmed by flow cytometry. For example, in established line U-87, a 20.5% decrease in thymidine uptake and a 
28.5% decrease in absorbance on the MTT assay produced by tamoxifen at 1 was associated with an increase in 
Ki-67 labeling from 42% to 62%; staurosporine, which produces a 78.8% decrease in thymidine uptake in cell line A- 
172 at lOnM , produced an increase in Ki-67 labeling from 19% to 32%. In this regard, Ki-67 labeling of glioblastoma 
tissue from a patient treated with high-dose tamoxifen yielded results within the range of 10% to 15% (consistent with 
values seen in untreated glioblastoma), despite tumor regression with treatment. The authors’ interpretation of these 
results is that these PKC inhibitors are halting the cell cycle in the G( phase or the G (-S  transition (beyond G0 but 
before S-phase), resulting in a paradoxical increase in labeling while arresting growth. Two important implications 
from these observations are that Ki-67 is not a reliable indicator of cellular proliferation after treatment with PKC 
inhibitors and that these inhibitors used at the doses given above halt cell growth in a phase-specific manner.
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j r  a l i g n a n t  gliomas possess very high protein ki- 
\ / I  nase C (PKC) activity when compared to non- 
V  .L  transformed glia, and PKC activity is strongly 
correlated to the growth rates of these tumor cells in 
vitro? "5 Surgically resected frozen human glioma speci­
mens also display elevated PKC activity w ith  in the range 
measured in established glioma lines.4 This elevated PKC 
activity may function as a target for inhibition of glioma 
growth in vitro,'•3~~5>14 and is currently being evaluated with 
some success in clinical trials for use as a chemotherapeu­
tic target in vivo.2,6,18
The monoclonal antibody Ki-67 recognizes a nuclear 
antigen expressed in the G]5 S, G„ and M phases of the 
cell cycle.9,11’13’15^ 17’19 It has been used extensively in recent 
years both as a laboratory and a clinical index of tumor 
proliferation. The present study was undertaken to evalu­
ate the accuracy of Ki-67 as an indicator of tumor prolif­
eration following treatment with PKC inhibitors and to 
explore the cell-cycle specificity of the growth inhibition 
produced by these agents. The authors demonstrate that 
the use of Ki-67 following PKC inhibition is an unreliable 
indicator of glioma proliferation in vitro  and in vivo. 
Clinical evaluation of tumor kinetics following treatment 
with PKC inhibitors may require the use of alternative 
measures of proliferation.
M ateria ls  a n d  M ethods
Glioma Cell Cultures
The previously characterized human malignant glioma 
cell lines A -172 and U-87 were used for the purposes of
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this study.* Cell lines were maintained in 25-cm2 tissue 
culture flasks, in medium consisting of Eagle’s minimum 
essential medium supplemented with 1 0 % fetal calf serum 
(FCS), gentamicin (20 |xg/ml), glutamine, pyruvate (1 
mM), dextrose (0.1%) and essential amino acids, buffered 
to a pH of 7.0.f  Cells were grown at 37°C in a humidified 
5% CO, incubator. All cell lines were routinely tested for 
mycoplasma contamination and passaged regularly.
In Vitro Glioma Proliferation A ssays
[3H]Thymidine Uptake. Our method for determining 
rates of glioma proliferation has been previously report­
ed.3-4 Following passage, each cell line was seeded at a 
density of 104 cells in 40 |xl of medium on 12-mm glass 
coverslips placed in 24-well culture plates. Coverslips 
were previously coated with 10 |xg/ml poly-L-lysine to 
facilitate cell adherence. Twelve hours later, after ade­
quate time for cells to adhere to the coverslips, the wells 
were flooded and washed with phosphate-buffered saline 
(PBS). After addition of 1 ml feeding medium (containing 
10% FCS) to each well, each PKC inhibitor was then 
added to the wells at predetermined concentration in trip­
licate. Following a 48-hour treatment period, wells were 
pulsed with 1 |xCi/ml pH]thymidine for a period of 6  
hours prior to harvest. To measure thymidine uptake, the 
coverslips with adherent cells were washed four times 
with PBS and placed in scintillation vials containing 5 ml 
scintillation fluids for determination in a (3-counter. It has 
been previously demonstrated that uptake of [3H]thymi- 
dine into cells by this technique is a reliable index of 
deoxyribonucleic acid (DNA) synthesis. 1
M7T Assay. As an additional method of measuring cel­
lular proliferation, a colorimetric assay using 3-(4,5- 
dimethyl-2 -thiazolyl)-2 ,5-diphenyl tetrazolium bromide 
(MTT) was performed following the addition of the PKC 
inhibitors. Glioma cells were seeded at a density of 2 X 
1 0 3 cells/well in 1 0 0  |xl feeding medium in flat-bottomed 
96-well plates. Following adherence in 100 |xl medium, 
the test agents were added in predetermined concentra­
tions, in quadruplicate, to achieve a total volume of 2 0 0  
ixywell. After incubation for 48 hours as above, 20 |xl 
MTT prepared at a concentration of 5 mg/ml in PBS was 
added to each well for 6  hours. The supernatant was 
decanted, and the MTT formazan precipitate was solubi­
lized by addition of 150 |xl 100% dimethyl sulfoxide and 
placed on a plate shaker for 10 minutes.§ Absorbance 
at 570 nm was determined on a spectrophotometric 
microplate reader.||
Staining With Ki-67. The Ki-67 staining was quantitated 
immunohistochemically and by flow cytometry. For 
microscopic immunostaining of glioma cell lines, cells
* M alignant gliom a cell lines A -172 and U -87 obtained from  
A m erican T ype C ulture C ollection, R ockville, M aryland.
t  M edium  constituents obtained from  G IBCO , G rand Island, New 
York.
t  C ytoscint scintillation fluid obtained from  ICN C hem ical, Irvine, 
California.
§ M TT and dim ethyl sulfoxide obtained from  Sigm a C hem ical Co., 
St. Louis, M issouri.
|| Spectrophotom etric m icroplate reader, M odel M R 700, m anufac­
tured by D ynatech, Chantilly, V irginia.
were seeded and grown on coverslips, treated for 48 hours 
with the PKC-inhibiting agents, and fixed with acetone 
for 5 minutes at room temperature. Following rehydra­
tion with PBS, the Ki-67 antibody* (diluted 1:30) was 
added to cover the cells for 2  hours at room temperature. 
Following three washes with PBS, anti-mouse biotinylat- 
ed antibodyf (1:10 dilution in PBS) was added at room 
temperature and allowed to incubate for 2 0  minutes. 
Following three washes in PBS, streptavidin-peroxidase 
reagent (1:20 dilution in PBS) was added to the coverslips 
and incubated for 20 minutes. After an additional wash, 
aminoethyl carbizole chromogen solution was added.t 
(All reagents except for the primary antibody were 
obtained in kit form and were diluted from the stock solu­
tion as recommended by the manufacturer.) The cover­
slips were then washed in PBS, counterstained with hema­
toxylin solution ( 1 0  minutes), and mounted for viewing.
For flow cytometric staining, cell lines were treated for 
48 hours with the agents as detailed above. Then the cells 
were removed using gentle trypsinization (0.05% for 10 
minutes) and washed three times in PBS after inactivation 
of the trypsin with FCS. Cells were fixed for a period of 1 
hour in a solution of 4% paraformaldehyde at 4°C. Fol­
lowing three washes in PBS, immunocytochemical Ki-67 
staining was performed in 1.8-ml Eppendorf tubes using 
30 |xl primary antibody for 1 hour (mouse anti-Ki-67; vol­
ume to achieve saturation of antigen)§ followed with 
equivalent volumes of anti-mouse secondary antibody 
conjugated with fluorescein isothiocyanate for 1 hour. 
Each stain was followed by three washes with PBS. The 
samples were analyzed with the flow cytometer to quanti­
tate the amount of immunofluorescence specifically relat­
ed to Ki-67 staining. Gating for acquisition of single cells 
was performed, and 1 0 4 events were acquired from each 
culture for analysis.
The Ki-67 antigen staining of glioma tissue obtained 
from a patient treated with high-dose tamoxifen was per­
formed using MIB-1 antibody.! Five 1-^m paraffin sec­
tions were deparaffinized and stained as previously 
described10 using the avidin-biotin complex method and 
an automated immunostaining device* after microwave 
treatment of tissue sections in antigen retrieval solution.f
DNA Cytofluorometry o f  Glioma Cultures. To confirm the 
results of the pH]thymidine incorporation, DNA cell- 
cycle analysis was performed by propidium iodide stain­
ing with analysis by flow cytometry. Cells were initially
X
25-cm2 tissue culture flask, in 5 ml glioma feeding medi­
um described above (containing 10% FCS). After ade-
* M onoclonal antibody K i-67 obtained from  D akopatts, G lostrup, 
D enm ark.
t  A n ti-m o u se  b io tiny la ted  antibody  ob tained  from  B iogenex 
Laboratory, San Ram on, California.
t  S trep tavid in-peroxidase reagent and am inoethyl carbizole chro­
m ogen solution obtained from  Zym ed, South San Francisco, California.
§ M ouse anti-K i-67 antibody obtained from  D akopatts, G lostrup, 
D enm ark.
|
* A utom ated  im m unostain ing  dev ice, M odel T echm ate  1000, 
obtained from  T echm ate Inc., G oleta, C alifornia.
t  A ntigen retrieval solution obtained from  Biogenex, San Ram on, 
California.
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Fig. I. Graphs showing growth inhibition of glioma ccll lines U-87 and A-172 by the protein kinase C (PKC) 
inhibitors staurosporine and tamoxifen, using pH]thymidine assay. The PKC inhibitors reduced pH]thymidine uptake in 
a dose-dependent manner in both cell lines. Values for glioma uptake of pH]thymidine represent counts per minute and 
are the mean ± standard error of t o  mean for triplicate wells. * = p <  0.05, ** = p <  0.01 (one-way analysis of vari­
ance, Duncan’s multiple comparison).
quate time for cell adherence ( 1 2  hours), the m edium  was 
changed and fresh medium containing the PKC inhibitors 
in the concentrations outlined below was added. The cul­
tures were maintained for a period of 48 hours, after which 
the cells were trypsinized, washed three times in PBS, and 
fixed by resuspension (106 cells/ml) in a solution of PBS 
and ice-cold methanol ( 1 : 2  final concentration, vortexing 
the cells to avoid clumping) for a period of 1 hour at 4°C. 
The staining protocol is adapted from that of Hurley.:!: 
After fixation, cells were centrifuged, supernatant was 
decanted, and 0.5 ml propidium iodide stain solution was 
added. This stain solution contained 10 mg propidium 
iodide, 0.1 m l Triton X-100, and 3.7 mg ethylenediamine 
tetraacetic acid in 100 ml PBS. Immediately following 
addition of the stain solution, 0.5 ml ribonuclease solution 
(10 mg ribonuclease mixed with 5 ml PBS and heated to 
75°C for 30 minutes before use) was added to eliminate 
double-stranded ribonucleic acid that would interfere with 
DNA quantification.§ Samples were analyzed on a fluo­
rescent-activated cell sorter|| after a 1 -hour staining period
$ Preparation of alcohol-fixed whole cells from suspensions for
DNA analysis. Becton Dickinson Source Book, Section 1.11, 1989.
§ Propidium iodide obtained from Calbiochem , San Diego, 
California; other reagents obtained from Sigma Chemical Co., St. 
Louis, Missouri.
|| FACScan fluorescent activated cell sorter manufactured by Becton 
Dickinson, San Jose, California.
at 37°C in the dark. Ten thousand events were acquired for 
analysis.
Results
Glioma Cell Line Proliferation Assays
As has been dem onstrated in previous reports , 1'4'5 
[3H] thymidine incorporation into the established glioma 
cell lines U-87 and A-172 decreased in a dose-related 
m anner after the addition of staurosporine or tamoxifen 
for a 48-hour period (Fig. 1). Similarly, by M TT assay 
these cell lines exhibited decreased absorbance (correlat­
ing with cell numbers) following the addition of these 
agents (Fig. 2). The M TT assay demonstrated a linear 
relationship between cell counts and optical density 
(Fig. 3).
Staining With Ki-67
Under treatment conditions identical to those described 
in the growth assays above, staurosporine and tamoxifen 
were added to cultures of the U-87 and A-172 glioma lines 
in logarithmic phase growth in medium containing 1 0 % 
FCS. In contrast to the assay results given above for 
[3H]thymidine and MTT, Ki-67 staining increased with 
the treatments (Fig. 4). Demonstrative photomicrographs 
of cell line U-87 stained with Ki-67 are presented in Fig. 
5. The relative amount of Ki-67 staining among a popula­
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Fig. 2. Graphs showing growth inhibition of glioma cell lines U-87 and A-172 by the protein kinase C (PKC) 
inhibitors staurosporine and tamoxifen, using 3-(4,5-dimethyl-2-tliiazolyl)-2,5-diphenyl tetrazolium bromide (MTT) 
assay. The PKC inhibitors decreased optical absorbance in a dose-dependent manner in both cell lines. Optical density 
values represent the mean ± standard error of the mean for quadruplicate wells. * = p <  0.05, ** = p <  0.01 (one-way
DNA Flow Cytometry o f  Glioma Cultures
Figure 7 shows DNA profiles of glioma line U-87 
grown in medium containing 10% FCS, either alone or in 
the presence of PKC inhibitors for 48 hours. In accor­
dance with the [3H]thymidine assay results, tamoxifen and 
staurosporine produced a dose-dependent decrease in the 
DNA synthesis phase (S-phase) of the tum or compared to 
the untreated control, indicating that the arrest o f the cycle 
was preferentially prior to entrance into the S-phase, as 
previously described .5 At very high doses o f staurosporine 
(100 nM), an increase was also noted in the G,/M peak 
(Fig. 7 upper right).
Increased K i-67 Staining in Glioma Tissue Treated With 
H igh-Dose Tamoxifen
Figure 8  dem onstrates Ki-67 antigen staining of 
glioblastoma tissue resected from a patient treated with 
high-dose tamoxifen. Note the high index of Ki-67 stain­
ing in this tumor (consistent with values seen in untreated 
glioblastom a161719). The patient has demonstrated a dra­
matic clinical response to treatment, having survived 36 
months thus far on tamoxifen therapy ( 1 0 0  mg twice 
daily) with continuing tumor regression .6
Discussion
The PKC signal transduction system activity is overex­
analysis of variance, Duncan’s multiple comparison).
tion of A-172 cells was compared by flow cytometry (Fig.
6 ); sim ilar results were obtained, dem onstrating an 
increase in relative Ki-67 staining among the cultures 
treated with the PKC inhibitors.
Fig. 3. Graph illustrating standardization of the 3-(4,5- 
dimethyl-2-tliiazolyl)-2,5-diphenyl tetrazolium bromide (MTT) 
assay and demonstrating the linear relationship between cell counts 
and optical density as measured by this technique.
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Fig. 4. Graphs showing amount of immunohistochcmical staining for Ki-67 antigen in glioma lines U-87 and A-172. 
In contrast with the results of the pH]thymidinc and MTT assays (Figs. I and 2), the number of cclls that stained posi­
tive for the Ki-67 antigen increased in a dosc-rclatcd manner with tamoxifen treatment of glioma line U-87 (upper) and 
similarly increased with both tamoxifen and staurosporine treatment of glioma line A-172 (lower). Values represent the 
mean of three separate microscopic fields, with a total of 1000 cclls counted per treatment group. All counts were pcr-
< <
parison).
pressed in gliomas in comparison to nontransformed glia 
and correlates strongly with proliferation rates of gliomas 
in vilro.3~5 Tamoxifen, in a property distinct from estrogen 
receptor blockade, inhibits PKC in established and some
low-passage glioma cell lines in the low-micromolar con­
centration range . 1 Although not a particularly potent 
inhibitor of PKC, tamoxifen is currently being investigat­
ed for therapeutic efficacy in patients harboring recurrent
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Fig. 5. Photomicrographs of cell line U-87 showing immunohistochcmical staining for Ki-67 antigen. The control cul­
ture (left) demonstrates few stained nuclei, whereas administration of staurosporine (10 nM) increased the staining 
markedly (right). Hematoxylin, original magnification X 200.
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Fig. 6. Overlay histogram plots demonstrating cytofluorometric analysis of Ki-67 staining. X-axis = logarithmic flu­
orescence units. Solid lines represent A-172 control culture and dotted lines 48 hours of incubation with either 10 
tamoxifen (left) or 10 nM staurosporine (right). Both plots demonstrate a shift in fluorescent intensity related to increased 
Ki-67 staining.
malignant gliom as .2-618 The potential for this type o f ther­
apy has engendered clinical trials utilizing more potent 
and specific inhibitors of PKC for patients harboring 
malignant gliomas.
In the present study, the relatively specific PKC 
inhibitor staurosporine and the less selective inhibitor 
tamoxifen both inhibited the growth o f malignant glioma 
cell lines in a dose-related manner, as has been noted in 
previous reports . 1-5 In contrast, both agents paradoxically 
increased Ki-67 labeling in the glioma cell lines within the 
same concentration range that produced growth inhibition 
as measured by cell counting, [3H] thymidine uptake, and 
M TT assay. Although PKC inhibition is a likely candidate 
for the mechanism o f this growth inhibition and is con­
sistent with the concentrations necessary to inhibit the 
enzyme in these cells , 1-3-4 we cannot exclude the possibili­
ty of other kinase inhibition or other pleiotropic effects of 
these agents that might contribute to the phase-specific 
growth arrest produced by these agents in this study.
The monoclonal antibody Ki-67 recognizes a nuclear 
antigen expressed in the G r  S, G „ and M  phases o f the 
cell cycle.9-11-15-18- This antigen has recently been cloned 
and sequenced, and is ahigh-m olecular-weight short-lived 
nonhistone nuclear protein, which may be an absolute 
requirement for maintaining cell proliferation .15 In the 
present study, measures o f glioma cell proliferation using 
pHlthym idine uptake, M TT assay, and cytofluorometric 
DNA analysis yielded consistent results, in that the PKC 
inhibitors produced an inhibition of cell growth. Par­
adoxically, under identical conditions, the Ki-67 index 
increased after these treatments; these apparently diamet­
ric results may be rationalized by examination o f the DNA 
cytofluorometric results, which indicate phase-specific 
cell growth arrest following these treatments (Fig. 7). The
DNA histograms indicate that cell growth is arrested prior 
to initiation of the S-phase , 12 in the Gy/Gj peak, producing 
a reduction in the proliferation index (defined as %S + 
%G,/M) as noted previously .5 As the antigen recognized 
by Ki-67 is expressed in the G, phase, in addition to the S, 
G„ and M  phases , 15-16 the staining would actually increase 
as a result o f growth arrest in this phase. This interpreta­
tion is supported by an increased population of lightly 
stained cells in the staurosporine- and tamoxifen-treated 
cells in the present study (Fig. 5) indicative o f growth 
arrest in the early cell cycle. In this regard, Crissman, et 
a l.,1 have also recently noted Gj-phase growth arrest o f 
nontransformed cells by staurosporine. In a subsequent 
study , 8 the same group reported that staurosporine may 
induce a G , block in a mouse mammary carcinoma line 
when used in higher concentrations, presumably mediated 
by blocking of p34cilc2 and p34alc2-like kinase activity .8 
This nonspecific kinase inhibition at higher concentra­
tions may also explain the increase in the number o f cells 
arrested in the G ,/M  peak noted in the present study when 
the glioma cells'w ere treated with 100 nM staurosporine 
(Fig. 7). It is noteworthy that blockage of the cells at either 
o f these points in the cell cycle could paradoxically in­
crease Ki-67 staining, although this assay was not per­
formed by Crissman and colleagues. Shiraishi, 16 using an 
immunoelectron microscopic analysis of Ki-67 staining, 
has noted staining patterns that were phase-specific (start­
ing with early Gj phase staining in the nucleoplasm); this 
work indicated that the antigen recognized by the anti­
body may be related to the processing and assembly of 
preribosomal particles.
In conclusion, the data from  the present study underline 
a potential pitfall with the use o f a single labeling study for 
determining the proliferation rate of malignant gliomas in
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Fig. 7. Graphs demonstrating cytofluo- 
romctric dcoxyribonuclcic acid (DNA) pro­
files of glioma line U-87. X-axis = arbitrary 
fluorescence units. Cells were grown in 
medium containing 10% FCS, either alone 
or in the presence of protein kinase C (PKC) 
inhibitors for 48 hours. Computer-generated 
estimate curvcs demonstrate that in accor­
dance with the pH]thymidinc assay results, 
staurosporine (upper center and right) and 
tamoxifen (lower) produced a dosc-dcpcn- 
dcnt decrease in DNA synthesis (S-phasc) 
of the tumor compared to the untreated con­
trol (upper left). Note that following treat­
ment with the PKC inhibitors the cells arc 
collecting in the G^Gj peak; halting of cell 
growth in the G, phase will paradoxically 
increase the Ki-67 staining, as the antigen 
recognized by the Ki-67 antibody is also 
expressed in this stage.
Fig. 8. Photomicrograph showing Ki-67 antigen staining of a recurrent astrocytoma in a patient treated with high-dose 
tamoxifen. The original biopsy from this patient revealed glioblastoma multiformc (Grade IV astrocytoma). H & E. 
Ijeft: The current biopsy reveals a predominantly gcmistocytic malignant astrocytoma with necrosis. Original magnifi­
cation X 16. Right: The five most proliferative fields were chosen to avoid areas of necrosis. All tumor cell nuclei were 
counted (a minimum of 1000 cells) and the percentage of positively stained nuclei determined. Immunopcroxidasc stain 
for Ki-67 using MIB-1 shows that 10% to 15% of cells arc immunorcactivc despite dramatic tumor regression on tamox-
X
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vitro. Moreover, clinical use of Ki-67 staining from in vivo 
surgical specimens must be interpreted with caution fol­
lowing treatment with kinase inhibitors, given the high 
labeling index demonstrated in the patient in this report in 
whom a dramatic clinical response has been obtained. In 
consideration of the Ki-67 staining results, together with 
the DNA cytometric analysis following treatment with 
PKC inhibitors, it appears that the inhibitors slowed tumor 
growth in a phase-specific manner.
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